RECENT NEWS

Flow cytometry is a mainstay of analytical methods to study cells, but growth is now accelerating as new immuno-oncology and liquid biopsy markets create unprecedented investment in the race to cure cancer.

Porosome Therapeutics has announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer’s Disease (AD) research and treatment by offering a new approach that goes beyond symptom management.

Inuvi, a leading UK provider of mobile phlebotomy, health assessments, blood testing, and community diagnostic services, has announced the opening of its new Diagnostic Centre. The facility opened in July on Wimpole Street, located within the Harley Street Health District. Purpose-built to meet the growing demand for fast and reliable blood testing, the clinic offers a convenient high-quality service for Inuvi’s customers.

There is an urgent need for a change in the law, backed up with Medicines and Healthcare products Regulatory Agency (MHRA) regulation, for many DIY diagnostic tests, says Dr Martin Myers, Consultant Clinical Biochemist, Joint Clinical Lead at NHSE Getting it Right First Time (GIRFT), Pathology. Laboratory Director Clinical Biochemistry & Clinical Lead for POCT at Lancashire Teaching Hospital.

Paige, a leader in next-generation AI technology, has announced the release of PRISM2, its most advanced slide-level foundation model to date. PRISM2 is designed to advance large language models (LLM) by enabling them to understand pathology images, connecting visual patterns with the clinical language used by clinicians to unlock novel capabilities.

Roche has received the CE Mark for its Elecsys pTau181 test to measure phosphorylated Tau (pTau) 181 protein, which is an indicator of amyloid pathology, a hallmark of Alzheimer’s disease.

US biotechnology firm Spear Bio has announced the commercial launch of its SPEAR UltraDetect immunoassay solution, delivering unparalleled sensitivity, specificity, precision, and scalability for robust biomarker measurement.

The UK Health Security Agency (UKHSA) has appointed Professor Robin May as Interim Chief Scientific Officer on a one-year appointment.

Molecules exhaled in the breath may help detect blood cancer, according to new research from Queen Mary University of London.

The Serious Hazards of Transfusion (SHOT) scheme has launched the UK’s first blood transfusion information app, co-created with patients, for patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced new measure to modernise and reduce regulations to improve patient access to innovative technologies.

Alpha Laboratories has been acquired by Diploma, a FTSE 100 UK-listed group specialising in value-added technical products and services across life sciences, seals, and controls. Diploma will add value by providing essential products and solutions through a decentralised, customer-orientated approach within each of its end markets.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Accounts, and accompanying Impact Report, demonstrating how it has enhanced patient safety across the UK, restored performance to meet regulatory timelines, and successfully enabled access to life-changing medical products.

Linkam Scientific Instruments is showcasing a range of microscopy stages and instrumentation at this year’s Microscopy & Microanalysis conference, including its core stages, new products, and its cryogenic temperature portfolio.

The UKHSA will see its operations move from its current sites in Porton Down, Wiltshire and Colindale in North London to a new National Biosecurity Centre (NBC) in Harlow, Essex, after Government funding for the project was confirmed.

The Government has launched its new Life Sciences Sector Plan as part of its flagship Industrial Strategy, setting out a ten-year mission to harness British science and innovation to deliver long-term economic growth and a stronger, prevention-focused NHS.

The Microbiology Society has expressed concern over the UK Government’s decision to cut funding to the Fleming Fund, a flagship global health programme working to combat antimicrobial resistance (AMR) in low- and middle-income countries (LMICs).

Genomics England will help deliver the 10 Year Health Plan through its digital systems and by generating the evidence to inform how genomics could be embedded into routine care - shaping future approaches to earlier diagnosis, prevention and more personalised treatment.

Waters Corporation and Becton Dickinson (BD) have announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies.

Bio-Techne has announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology.